Nammi Therapeutics Awarded Grant by California Institute for Regenerative Medicine (CIRM)
Updated: Feb 9, 2023
The governing Board of the California Institute for Regenerative Medicine (CIRM) funded a Phase 3 clinical trial to support the development of a safer, more tolerable alternative.
The CIRM Board awarded $3,999,113 to Dr. David Stover and Nammi Therapeutics to complete the manufacture and testing needed to gain FDA permission for a clinical trial for multiple myeloma and advanced solid tumors. The therapy QXL 138AM, a “masked immunocytokine,” binds to and kills the tumor by activating the immune system.